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S U M M A R Y 
In this work, an attempt was made to induceng resistance to 3 schistosomi¬ 
cidal drugs in a Brazilian strain of S. mansoni, according to the Type II re-
sistance induction scheme proposed by JANSMA et al. in 1977. Three attempts 
were unsuccessful. The parental generation treated with the drug during the 
immature stage of the worm was less susceptible to the chemotherapeutic agents 
than generations F1 and F 2. A hypothesis is suggested as an explanation. 
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I N T R O D U C T I O N 
In Brazil, Schistosomiasis mansoni is an 
important endemic disease, in several States9, 
affecting about 10% of the Brazilian popula-
tion. Many control program have been imple-
mented, mostly employing chemotherapy as 
one of the main prophylactic methods to fight 
this parasitosis. 
Mass treatment is currently being underta-
ken in Brazil using oxamniquine, with relative 
success, since the susceptibility of the Brazi-
lian strains of S. mansoni to chemotherapeu-
tic agents is reasonably good. Nevertheless se-
veral human strains resistant to oxamniquine 
have been described in Brazil 2,3,4,53. Fortuna-
tely, the resistance phenomenon so far seems 
not to be an^pidemiological problem since the 
cases of resistant worms are not numerous 
and, whenever tested, these strains showed 
susceptibility to praziquantel1,*. It is easy to 
foresee, however, the negative repercussions of 
a strain of S. mansoni resistant to oxamniqui-
ne and/or other chemotherapeutic agent which 
might spread out in a given region. 
Research on the mechanism of resistance 
development started with Rogers and Bueding, 
who, using mice infected in the laboratory, 
succeeded in experimentally induce resistance 
to hycanthone and oxamniquine in the proge-
ny of worms treated with subtherapeutical do-
ses of hycanthone13. 
JANSMA et al. 7 induced resistance to hy-
canthone and oxamniquine in the progeny of 
worms experimentally manipulated (further 
resistance) in 3 out of 5 strains of S. mansoni 
via three induction schemes. Type I resistance 
was obtained by means similar to those used 
by ROGERS & BUEDING 1 3 . Type II resistan-
ce was induced by treating mice harbouring 
the parental worm generation with subthera-
peutic dosages of the drug at the time of the 
immature stage of infection, during the em-
briological development of the reproductive 
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system. Type III resistance was produced by 
infection of mice with cercariae of only one 
sex, followed by infection with cercarie of the 
opposite sex 2 to 58 weeks later, which didn't 
have any contact with the drug. The three types 
of resistance were limited to the progeny of 
the parental worms which showed susceptibi-
lity to the drugs used. 
Theoretically, all these methods for pro-
ducing resistance to S. mansoni could be inad-
vertently reproduced in the field, where mass 
treatment is frequently carried out indiscrimi-
nately. We believe that an experimental study 
on the resistance development possibility of in 
human strains of S. mansoni to certain drugs 
is very important, specially for determining the 
chemotherapeutic agent of choice for mass 
treatment of a population. 
MATERIALS AND METHODS 
1. S. mansoni strain 
A Brazilian strain of S. mansoni, kept in 
our laboratory for several years, was used. It 
•was isolated from a patient infected in Belo 
Horizonte, Minas Gerais, Brazil, and was na-
med BH strain. In previous studies, this strain 
has already shown susceptibility to oxamniqui-
ne, praziquantel, niridazole and nyanthone4. 
2. S. mansoni hosts 
Female albine mice (Mus musculus) weigh-
ing approximately 15 g at infection were used 
as definitive host. Intermediate hosts were 
laboratory raised albine Biomphalaria glabra-
ta, descendant from molluscs captured in Be-
lo Horizonte, Minas Gerais, Brazil. 
3. Drugs and dosages 
a — For induction: 
oxamniquine — 50 mg/kg, single dose; ol-
tipraz — 60 mg/kg daily for 5 days: pra-
ziquantel — 50 mg/kg daily for 5 days. 
b — For effective treatment and assessment 
of susceptibility: oxamniquine — lOOmg/ 
kg, single dose; oltipraz — 125mg/kg dai-
ly for 5 days; praziquantel — 100mg/kg 
daily for 5 day; all drugs were given orally 
by gavage. 
4. Induction scheme 
Three groups of mice infected through the 
tail 1 0 with 70 cercariae of S. mansoni were 
treated with one of the drugs during the imma-
ture stage of infection, during the time of the 
embriological development of the genital or-
gans of schistosomules of both sexes (between 
days 26 and 30, or on the 28th day after infec-
tion, according to the posology), in an attempt 
to induce drug resistance (Fig. 1). 
Each group was then divided into 2 sub-
groups: trial and control. The animals in the 
trial subgroup were treated again, this time 
with therapeutic dosages of the respective 
drug, 60 days after the cercarían infection. 
After 20 days the animals of both subgroups 
were killed with a blow on the neck. Perfu-
sion of the porta-mesenteric venous system and 
oograms of the small intestine were carried 
OUt 12,16. 
The faeces of the animals in the control 
subgroup were used to obtain miracidia of F t 
generation, 'which were used for mass infection 
of B. glabrata14. The control subgroup was 
also used as standard for measuring the sus-
ceptibility of the trial subgroup. 
After elimination of the cercariae from 
B. glabrata infected with F, generation, new 
groups of mice were inoculated through the 
tail with 70 cercariae. 
Sixty days after the cercarian infection, 
the 3 groups of F, mice were divided into 2 
subgroups: trial and control. The mice in the 
trial subgroup were treated with therapeutic 
dosages of the respective drug. Twenty days 
after the treatment, the animals in both sub-
groups were killed, and perfusion and oograms 
of the small intestine were performed 12-is. 
A similar scheme was applied to F, gene 
ration. 
¡5. Susceptibility criteria 
a — Worm distribution. 
The usual worm distribution pattern in 
the porta-mesenteric system obtained by per-
fusion was supplied by the control group. The 
finding of high percentages of worms in the 
liver of animals in the trial subgroup was the 
evidence of the susceptibility of the worm to 
the schistosomicidal agent*1. 
b — Percentage of oogram alterations 
Oogram alterations were considered signi-
ficant in the absence of one or more stages of 
immature eggs. This fact indicated interrup-
tion of oviposition, and hence, parasite sus-
ceptibility to the drug 
c — Percentage of worm reduction: 
GONNERT & ANDREWS 6 estimated this 
rate by using the following formula: 
Percentage of worm reduction = 
number of dead schistosoma 
= 100 x 
number of live and dead schistosoma 
d — Percentage of surviving worms: 
This was obtained in accordance to the 
formula proposed by JANSMA et al 7 : 
T x 100 
Percentage of surviving worms = 
C 
where: 
T is the average number of live worms per 
animal found in the trial group and C is the 
average number of live worms per animal 
found in the control group. 
e — Reduction of parasite load 
A significant reduction of the parasite load 
in the trial subgroup compared to the control 
subgroup indicates the susceptibility of the 
worm to the drug 1 1 . 
RESULTS 
The percentage of males (Table I) was es-
tablished in order to safely use the criterion 
of "worm distribution", because in the case of 
poorly balanced inoculations, with predomi-
nance of one sex, there is a tendency towards 
the concentración of the worms in the liver 
and porta vein ^,17. in this way, the data of 
the concentration of the worms in the liver 
since there was a tendency in the trial sub-
group to present a higher percentage of males. 
After treatment it was more difficult to find 
female than male worms due to their small 
size, desintegraron and encapsulation in liver 
granulomas. 
In 3 generations the mean, percentage of 
males in all control subgroups was 58.1% with 
a standard deviation of 9.7%, varying from 
44.9% to 71.6% and thus compatible with the 
use of the "worm distribution" criterion for 
susceptibility analysis. 
Results were very similar in all therapeutic 
groups. The parenteral generation of the worm 
was susceptible to the 3 drugs used (Table I) . 
All trial subgroups presented large percentages 
of worms in the liver and porta vein, signifi-
cant reduction of parasite load compared to 
the control subgroup, high rates of worm re-
duction, low rates of surviving worms and 
100% change in oograms. These results occur-
red both in the parental generation and in ¥ l 
(Table I) , suggesting susceptibility of both ge-
nerations, and therefore, failure of the attempt 
to induce resistance. Analysis of the P 2 gene-
ration showed results nearly identical to F,. 
An interesting and unexpected finding in 
the experiment was that the parental genera-
tion showed lower susceptibility than ^ and 
P2 generations, since in the former some sur-
viving worms were still found after treatment, 
while in P t and P2 surviving worms were prac-
tically inexistent. 
DISCUSSION 
The results showed that when submitted 
to JANSMA et al. Type II resistance induction 
scheme with the 3 schistosomicidal drugs used, 
contrary to expected, the susceptbiility of S. 
mansoni strain increased in successive worm 
generations. This not only indicated failure 
in the attempt to induce resistance but also 
broadened the possibilities for production of 
resistance to schistosomicides in S. mansoni 
strains. Many explanations can be offered 
for the fact that the parental generation pre-
sent lower susceptibility than its progeny. The 
fact that the only difference in the manipula 
tion of parental and progeny generations was 
the treatment of the parental generation dur 
ing the immature stage of infection, lead us 
to raise the hypothesis that this treatment 
may have lowered the susceptibility of the pa-
rental generation, perhaps through an enzyma-

tic induction process. This observation may 
be of value and opens new fields of research 
on the mechanism of producing resistance to 
schistosomicidal agents in S. mansoni. 
Furthermore, failure in the attempt to in-
duce resistance to schistosomicides in a Bra-
zilian strain of S. mansoni is a good result, 
because it suggests a low potential of this 
strain to become resistant, in a country where 
mass treatment situations favour the develop-
ment of such a resistance. Nevertheless more 
trials must be undertaken to evaluate this po-
tential in relation to other brazilian strains, 
applying different induction schemes. 
CONCLUSIONS 
a. The JANSMA et al. Type II resistance in-
duction scheme failed to induce resistance 
to schistosomicidal drugs in the Brazilian 
strain of S. mansoni (BH from Minas Ge-
rais). 
b. The parental generation of S. mansoni 
treated with schistosomicidal drugs during 
the immature stage of infection showed less 
susceptibility than its progeny. Further re-
search must be carried out in order to de-
termine the effect that this type of exposu-
re may have on the susceptibility of the worm. 
RESUMO 
Insucesso na indução de resistência a drogas 
esquistossomicidas em uma cepa brasileira 
humana de Schistosoma mansoni 
No presente estudo, realizou-se uma ten-
tativa de indução de resistência a 3 drogas es-
quistossomicidas em uma cepa brasileira de 
S. mansoni, segundo o esquema de indução de 
resistência tipo II preconizado por JANSMA 
et al. em 1977. Houve insucesso nas 3 tentati-
vas realizadas. A geração parental tratada 
com a droga durante o estágio imaturo do 
verme mostrou-se menos suscetível aos quimio¬ 
terápicos do que as gerações F1 e F 2 do verme. 
Uma hipótese é levantada para a explicação 
do fato. 
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